This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VHL Family Alliance Launches New Website

BOSTON, Aug. 20, 2012 /PRNewswire/ -- The von Hippel-Lindau Family Alliance (VHLFA), the leading resource for von Hippel-Lindau (VHL) and related tumor conditions, is pleased to announce the launch of its new, user-friendly website, http://www.vhl.org.

The goal of the new site is to provide visitors with easily accessible information regarding research, treatment, and support. In upholding VHLFA's mission to improve diagnosis, treatment, and quality of life for individuals and families affected by von Hippel-Lindau disease, visitors will have the ability to navigate the site to obtain critical, up-to-date information regarding VHL.

"We are proud to release our updated and easy to navigate website," said Camron King, chair of the VHLFA website committee. "The site reflects months of work by members of the VHLFA community and highlights our mission of funding research and educating, supporting, and improving the lives of individuals and families affected by von Hippel-Lindau disease (VHL), kidney cancer, and hereditary cancers."

The VHLFA 20 year anniversary will also be marked with a Fundraising Dinner honoring Founding Executive Director, Joyce Graff and prominent VHL Researcher, Dr. William Kaelin of Dana-Farber Cancer Institute. Proceeds from this event will go towards critical research aimed at identifying a cure to VHL and other tumor-related cancers. To date, the VHLFA has awarded over $1.3M in research grants.

About VHLFA

The VHL Family Alliance (VHLFA), a 510(c)3 non-profit organization founded in Brookline, Massachusetts in 1993, is an international network of family support volunteers, researchers, and medical professionals. VHLFA is the preeminent resource for VHL and related tumor conditions. The VHL gene is a primary player on the path of angiogenesis and thus is one of the keys to understanding cancer. Like us on Facebook, find us on LinkedIn or follow us on Twitter.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs